Charting immune signaling proteomes en route to new therapeutic strategies

2Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

The activation state of an antitumor effector T cell in a tumor depends on the sum of all stimulatory signals and inhibitory signals that it receives in the tumor microenvironment. Accumulating data address the increasing complexity of these signals produced by a myriad of immune checkpoint molecules, cytokines, and metabolites. While reductionist experiments have identified key molecules and their importance in signaling, less clear is the integration of all these signals that allows T cells to guide their responses in health and in disease. Mass spectrometry-based proteomics is well poised to offer such insights, including monitoring emergence of resistance mechanisms to immunotherapeutics during treatments. A major application of this technology is in the discovery and characterization of small-molecule agents capable of enhancing the response to immunotherapeutic agents. Such an approach would reinvigorate small-molecule drug development aimed not at tumor cells but rather at tumor-resident T cells capable of producing dramatic and durable antitumor responses.

Cite

CITATION STYLE

APA

Haura, E. B., Beg, A. A., Rix, U., & Antonia, S. (2015). Charting immune signaling proteomes en route to new therapeutic strategies. Cancer Immunology Research, 3(7), 714–720. https://doi.org/10.1158/2326-6066.CIR-15-0094

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free